Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H11IN2O4 |
| Molecular Weight | 338.0991 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(I)C=NC2=O
InChI
InChIKey=XIJXHOVKJAXCGJ-XLPZGREQSA-N
InChI=1S/C9H11IN2O4/c10-5-2-11-9(15)12(3-5)8-1-6(14)7(4-13)16-8/h2-3,6-8,13-14H,1,4H2/t6-,7+,8+/m0/s1
| Molecular Formula | C9H11IN2O4 |
| Molecular Weight | 338.0991 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1316491/?page=1https://www.ncbi.nlm.nih.gov/pubmed/31337643 | https://clinicaltrials.gov/ct2/show/NCT02993146 | https://clinicaltrials.gov/ct2/show/NCT02381561 | https://www.drugbank.ca/drugs/DB06485Curator's Comment: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm;
http://www.ncbi.nlm.nih.gov/pubmed/9336833;
http://www.ncbi.nlm.nih.gov/pubmed/12705773;
http://www.ncbi.nlm.nih.gov/pubmed/14435162;
http://www.ncbi.nlm.nih.gov/pubmed/4309419
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1316491/?page=1https://www.ncbi.nlm.nih.gov/pubmed/31337643 | https://clinicaltrials.gov/ct2/show/NCT02993146 | https://clinicaltrials.gov/ct2/show/NCT02381561 | https://www.drugbank.ca/drugs/DB06485
Curator's Comment: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm;
http://www.ncbi.nlm.nih.gov/pubmed/9336833;
http://www.ncbi.nlm.nih.gov/pubmed/12705773;
http://www.ncbi.nlm.nih.gov/pubmed/14435162;
http://www.ncbi.nlm.nih.gov/pubmed/4309419
Ropidoxuridine is a thymidine analogue and an oral prodrug of iododeoxyuridine that is easier to administer and less toxic with a more favorable therapeutic index in preclinical studies. Iododeoxyuridine demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor. Ropidoxuridine may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. In 2019, phase I clinical trials were ongoing to study the best dose of ropidoxuridine and its side effects in patients with metastatic malignant neoplasm in the brain and in patients with metastatic gastrointestinal cancer. First results showed that ropidoxuridine, combined with radiation therapy, was well-tolerated in patients with metastatic gastrointestinal cancer.
CNS Activity
Originator
Approval Year
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
139.03 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9661893/ |
4538 mg/m² 1 times / day multiple, intraperitoneal dose: 4538 mg/m² route of administration: Intraperitoneal experiment type: MULTIPLE co-administered: |
IDOXURIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. | 1976 Mar |
|
| Interventions for herpes simplex virus epithelial keratitis. | 2003 |
|
| Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy. | 2003 Aug |
|
| Exploration of the influence of 5-iodo-2'-deoxyuridine incorporation on the structure of d[CACG(IDU)G]. | 2003 Aug |
|
| Efficient one-step Suzuki arylation of unprotected halonucleosides, using water-soluble palladium catalysts. | 2003 Aug 22 |
|
| Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans. | 2003 Aug 4 |
|
| Postherpetic neuralgia. | 2003 Dec |
|
| Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine. | 2003 Dec |
|
| [Anti-herpetic chemotherapeutic drugs]. | 2003 Feb |
|
| A balanced deoxyribonucleoside mixture increased the rate of DNA incorporation of 5-[125I]Iodo-2'-deoxyuridine in glioblastoma cells. | 2003 Feb |
|
| Novel agents and strategies to treat herpes simplex virus infections. | 2003 Feb |
|
| Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine. | 2003 Feb |
|
| Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. | 2003 Feb |
|
| Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. | 2003 Feb 1 |
|
| Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. | 2003 Feb 15 |
|
| In vitro activity of potential anti-poxvirus agents. | 2003 Jan |
|
| Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. | 2003 Jul |
|
| Postherpetic neuralgia. | 2003 Jun |
|
| Randomized, open-labelled comparison between an idoxuridine 10% gel and acyclovir 5% cream in recurrent herpes labialis. | 2003 Mar |
|
| Clinical significance of atomic inner shell ionization (ISI) and Auger cascade for radiosensitization using IUdR, BUdR, platinum salts, or gadolinium porphyrin compounds. | 2003 Mar 15 |
|
| Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine. | 2003 Mar-Apr |
|
| A simple and efficient method for synthesis of 5-substituted 2'-deoxyuridine nucleosides using metal-halogen exchange reaction of 5-iodo-2'-deoxyuridine sodium salt. | 2003 May 7 |
|
| Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors. | 2003 May-Aug |
|
| Biliary obstruction reduces hepatic killing and phagocytic clearance of circulating microorganisms in rats. | 2003 May-Jun |
|
| Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver. | 2003 Oct |
|
| Role of MutSalpha in the recognition of iododeoxyuridine in DNA. | 2003 Sep 1 |
|
| Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. | 2004 |
|
| In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. | 2004 Apr |
|
| Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. | 2004 Aug |
|
| Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals. | 2004 Aug |
|
| New tertiary constraints between the RNA components of active yeast spliceosomes: a photo-crosslinking study. | 2004 Aug |
|
| Synchrotron radiation-based experimental determination of the optimal energy for cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds. | 2004 Aug 2 |
|
| Effects of single-pulse (< or = 1 ps) X-rays from laser-produced plasmas on mammalian cells. | 2004 Dec |
|
| Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice. | 2004 Feb 18 |
|
| In vivo comparison of IVDU and IVFRU in HSV1-TK gene expressing tumor bearing rats. | 2004 Jan |
|
| Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. | 2004 Jan |
|
| Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2'-deoxy-2'-(fluoromethylene) cytidine and iododeoxyuridine. | 2004 Jul |
|
| Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. | 2004 Jul 15 |
|
| Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. | 2004 Jul 19 |
|
| Antiviral drugs in current clinical use. | 2004 Jun |
|
| Antisense thymidylate synthase electrogene transfer to increase uptake of radiolabeled iododeoxyuridine in a murine model. | 2004 Mar |
|
| Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk. | 2004 Mar |
|
| [The latest in herpes simplex keratitis therapy]. | 2004 May |
|
| Indian hedgehog: a mechanotransduction mediator in condylar cartilage. | 2004 May |
|
| The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy. | 2004 May |
|
| Polyphosphoinositides-dependent regulation of the osteoclast actin cytoskeleton and bone resorption. | 2004 May 13 |
|
| Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. | 2004 May 20 |
|
| Synthesis and antiviral activities of 1'-carbon-substituted 4'-thiothymidines. | 2004 Oct 15 |
|
| [Therapeutic effect of 125IUdR on the glioma cell line C6 in vitro and in vivo]. | 2004 Sep |
|
| Overexpression of p27 Kip 1, probability of cell cycle exit, and laminar destination of neocortical neurons. | 2005 Sep |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 00:03:01 UTC 2023
by
admin
on
Thu Jul 06 00:03:01 UTC 2023
|
| Record UNII |
3HX21A3SQF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C798
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
||
|
FDA ORPHAN DRUG |
519016
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
||
|
FDA ORPHAN DRUG |
222606
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
||
|
NCI_THESAURUS |
C1557
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
||
|
FDA ORPHAN DRUG |
690919
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
726188
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
C48813
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
3HX21A3SQF
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
C045889
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
9840777
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
DB06485
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
DTXSID00239353
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
8831
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
SS-20
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
93265-81-7
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
CHEMBL2103821
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY | |||
|
300000036831
Created by
admin on Thu Jul 06 00:03:01 UTC 2023 , Edited by admin on Thu Jul 06 00:03:01 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|